30 01, 2023

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2023-03-10T10:52:49+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Comments Off on TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2023-03-10T10:56:26+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|Comments Off on Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

23 01, 2018

TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

2023-03-10T11:00:13+01:00January 23rd, 2018|biomarkers, drug development, drug discovery, LMD, microRNA, microRNAs, Vivomicx|Comments Off on TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the [...]

Go to Top